We are 1-(2,3-Dichlorophenyl)piperazine hydrochloride CAS:119532-26-2 manufacturer and supplier in China, Pls send inquiry of to email@example.com of visit www.nbinno.com our official website should you have any interests
Chemical Name: 1-(2,3-Dichlorophenyl)piperazine hydrochloride
RARECHEM AH CK 0082
Physical and Chemical Properties:
Boiling point: 365.1ºC at 760mmHg
Refractive index: /
Appearance: White or off-white powder
Residue on ignition:≤0.5%
Loss on drying:≤0.5%
25kg cardboard drum or according to customer specified requirements
Storage:Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:Intermediates of Aripiprazole CAS:129722-12-9
Related News: In April 2019, Glenmark had received approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate after successfully completing Phase-3 clinical trials.2-amino-4-cloro-6-metoxipirimidina CAS:5734-64-5 Taking Minuo Huawei as an example, in 2016, the capacity utilization rate and production-sales ratio of its multiple drug substance varieties reached more than 90%. Therefore, domestic API companies have expanded their production capacity in recent years to meet the growing demand for APIs.Methyl 4,4-dimethoxy-3-oxobutanoate CAS:60705-25-1 In the early stage of market development, API companies usually need to strive to become a supply company for pharmaceutical companies after quickly completing product preparations. In the subsequent scale-up of production and market application, the relationship between pharmaceutical companies and API companies will become closer. The choice of R & D products of pharmaceutical companies will also be affected by pharmaceutical companies in turn.43039-98-1 According to the business type, it can be divided into non-CMO business of APIs and intermediates and CMO business of APIs and intermediates.ICIG will also supply materials needed for the manufacture of other treatments in earlier stages of development, including neo-GAA, currently in preclinical development as a potential next-generation Pompe disease therapy.